Friday, April 17, 2026
← Back to archivePolicy
Policy•Fierce Pharma•Apr 17, 2026
UPDATED: Heeding RFK Jr.'s call, FDA reclassifies 12 unapproved peptides ahead of advisory committee meeting
background ▾
- •FDA reclassified 12 peptides ahead of advisory committee review, signaling potential policy shift on compounded peptide access driven by RFK Jr.'s advocacy
- •Seven peptides are currently restricted from compounded use; the advisory committee meeting this summer will determine whether restrictions are modified
- •Monitor the summer advisory committee meeting outcome and any subsequent FDA guidance changes to compounding regulations that could expand peptide accessibility through non-traditional channels
FDApeptides (unspecified)
→ Read original articlePolicy•Fierce Pharma•Apr 17, 2026
Viatris, Teva kick off separate recalls over dissolution, raw material issues
background ▾
- •Two major generic/specialty pharma manufacturers have launched simultaneous recalls due to manufacturing and quality defects, signaling potential systemic quality assurance challenges
- •Recalls involve commonly prescribed medications (anxiety treatment and antihypertensive), potentially affecting large patient populations and generating regulatory scrutiny
ViatrisTeva Pharmaceutical IndustriesAnxiety medication (unspecified)High blood pressure patch (unspecified)
→ Read original articlePolicy•STAT News•Apr 17, 2026
Opinion: Health care is not ready for the new era of AI-enabled cyberattacks
background ▾
- •Healthcare cybersecurity defenses were not built for the pace of AI-enabled vulnerability discovery; vulnerability-to-exploit timeline has collapsed to under one day, requiring immediate 90-day preparedness plans across all healthcare organizations
- •Major recent breaches (Ascension, Change Healthcare) directly compromised patient care—74% of surveyed hospitals reported direct impact—yet the sector was excluded from early-access AI security programs offered to tech giants
- •The core vulnerability is structural, not technical: healthcare systems don't control their software stack and lack economic incentives to patch vulnerabilities rapidly; policy intervention and healthcare sector inclusion in coordinated disclosure programs are critical next steps
AnthropicBrockton HospitalAscension
→ Read original articlePolicy•STAT News•Apr 17, 2026
Opinion: Don’t believe headlines saying that vaccine skepticism is widespread
background ▾
- •The Politico poll's headline-driving question conflates four distinct beliefs into a binary choice, making it methodologically inappropriate to conclude that half of Americans are vaccine skeptical
- •Multiple peer-reviewed surveys over several years demonstrate slow erosion but overall resilient vaccine confidence—contradicting claims that skepticism is now widespread or the norm
Policy•Endpoints News•Apr 16, 2026
RFK Jr. defends FDA, Makary following Republican questions
background ▾
- •Kennedy publicly supported FDA Commissioner Makary amid Republican scrutiny, suggesting internal government alignment on FDA leadership
FDA
→ Read original articleMarket Access
Market Access•Fierce Pharma•Apr 17, 2026
Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
background ▾
- •FCB Health New York has been rebranded as Olixir New York under Omnicom Health's ownership post-acquisition
Omnicom HealthInterpublic GroupFCB Health
→ Read original articleMarket Access•Fierce Biotech•Apr 16, 2026
Johnson & Johnson hands back failed eye disease gene therapy to MeiraGTx
background ▾
- •J&J's $415 million acquisition of bota-vec in late 2023 resulted in a near-total loss ($25 million buyback), exemplifying the high attrition risk in gene therapy development and the substantial financial impact of phase 3 failures.
- •MeiraGTx claims post-hoc physician feedback and 'unprecedented improvements' in vision domains despite the failed primary endpoint, raising questions about trial design, endpoint selection, and the credibility of retrospective assessments.
- •FDA regulatory risk remains elevated: incoming leadership uncertainty and prior skepticism of gene therapies under outgoing CBER director Vinay Prasad create a hostile approval environment; MeiraGTx's path to 2027 launch depends entirely on reversing recent regulatory headwinds.
Johnson & JohnsonMeiraGTxbotaretigene sparoparvovec (bota-vec)AAV-hAQP1
→ Read original articleMarket Access•Fierce Pharma•Apr 17, 2026
Verily Health simplifies medical jargon alphabet soup with AI-powered app in new campaign
background ▾
- •Verily is investing in consumer-facing digital health tools to address patient health literacy around medical jargon
Verily Health
→ Read original articleMarket Access•Fierce Pharma•Apr 17, 2026
In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
background ▾
- •Daiichi Sankyo is selling its consumer health unit to Suntory for $1.5 billion to refocus on innovative oncology medicines
- •This move exemplifies a wider pharma industry trend of divesting consumer health assets to concentrate on high-value drug development
- •Monitor how Daiichi Sankyo deploys proceeds and whether the divestiture accelerates its oncology pipeline advancement
Daiichi SankyoSuntory
→ Read original articleMarket Access•Fierce Pharma•Apr 17, 2026
Gilead widens global Yeztugo access agreement, but MSF says supply is 'not nearly enough'
background ▾
- •Gilead and Global Fund expanded Yeztugo distribution commitment to 3 million patients by 2028, a material increase in stated access goals
- •MSF's public criticism signals that even expanded supply targets fall short of advocacy group expectations, raising questions about manufacturing constraints or pricing barriers
- •Monitor whether Gilead increases manufacturing capacity, adjusts pricing, or faces regulatory/reputational pressure to further expand access commitments
Gilead SciencesGlobal FundMédecins Sans FrontièresYeztugo
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 17, 2026
Small pools, big ideas: How the rare disease community is reimagining clinical trials
background ▾
- •FDA recently rejected external control designs in two high-profile rare disease programs (Biohaven troriluzole, uniQure AMT-130), citing methodological flaws in propensity score matching and concerns about subjective endpoint susceptibility to placebo effect
- •FDA is finalizing guidance on external controls for rare disease approvals, signaling intent to clarify acceptable methodologies but implying current practices are insufficient
- •Watch for: FDA's final external control guidance publication and its reception by sponsors; uniQure's dialogue with FDA on cUHDRS endpoint refinement; broader industry adoption of objective-only endpoints in external control trials
BiohavenuniQureFDAtroriluzoleAMT-130
→ Read original articleClinical Trials•Fierce Biotech•Apr 16, 2026
Eying 3 approvals in 2 years, Ocugen’s CEO wants to bring gene therapy to the masses
background ▾
- •OCU400 phase 3 trial for retinitis pigmentosa is described as the largest orphan gene therapy trial globally, with rolling FDA submission planned for 2024 and potential approval within two years
- •Ocugen's NR2E3-based approach targets multiple genetic causes of disease (>100 genes can cause RP) versus single-gene therapies, positioning it for larger addressable markets and better commercial viability
- •Monitor 2024 for phase 2/3 readouts in Stargardt disease and geographic atrophy, and track whether Ocugen achieves its three BLA target within the two-year window while maintaining its stated lower pricing strategy
OcugenSpark TherapeuticsRocheOCU400OCU410STOCU410
→ Read original articleClinical Trials•Pharmaceutical Technology•Apr 16, 2026
Developers back Alzheimer’s drugs despite report suggesting lack of efficacy
background ▾
- •Cochrane analysis of 20,342 patients found anti-amyloid drugs show no clinically meaningful cognitive benefit despite statistical significance, challenging the clinical value proposition of first-in-class disease-modifying Alzheimer's therapies
- •Manufacturers dispute methodology citing pooling of failed compounds with approved drugs, but acknowledge the core debate: whether slowing cognitive decline by 35% over 18 months meets patient/payer threshold for clinical meaningfulness
- •Watch for: regulatory and health authority responses to Cochrane findings; real-world evidence studies; potential impact on reimbursement coverage and formulary decisions by major payers; shift toward alternative therapeutic modalities in Alzheimer's pipeline
Eli LillyEisaiBiogendonanemabKisunlalecanemab
→ Read original articleClinical Trials•Fierce Pharma•Apr 17, 2026
Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy
background ▾
- •Roche is pursuing a new clinical study for Elevidys after EMA rejection, signaling confidence in the asset despite regulatory setback and shifting strategy from relying on patient advocacy to generating additional clinical data.
- •The EMA's rejection suggests significant efficacy or safety concerns that cannot be addressed through existing data, raising questions about the adequacy of Roche's initial clinical program design.
- •Investors and regulators should monitor the new study's design, patient population, primary endpoints, and timeline—any deviation from EMA guidance could result in another rejection, while success could lead to resubmission within 12-24 months.
RocheElevidysdelandistide moxeparvovec
→ Read original articleClinical Trials•Pharmaceutical Technology•Apr 16, 2026
Lilly debuts more Foundayo data as FDA requests post-marketing trials
background ▾
- •ACHIEVE-4 demonstrated cardiovascular non-inferiority and absence of hepatic toxicity, directly addressing FDA's primary safety reservations and de-risking the program
- •FDA imposed standard post-marketing trial requirements (pediatric, pregnancy, thyroid monitoring) rather than label restrictions, signaling regulatory confidence conditional on ongoing surveillance
- •Foundayo's competitive positioning depends on convenience and supply advantages over Wegovy, not safety differentiation, as post-approval requirements should not constrain commercial uptake
Eli LillyNovo NordiskFoundayoorforglipronWegovy
→ Read original article